Compare Fiverr International Ltd (FVRR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Incyte Corporation — how do they compare? Fiverr International Ltd trades at $8.74 (market cap $314.57M), while Incyte Corporation trades at $120.8 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 78× Fiverr International Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| FVRR | INCY | |
|---|---|---|
Market Cap | $314.57M | $24.54B |
Sector | Industrials | Health |
52-Week High | $26.67 | $129.93 |
52-Week Low | $8.75 | $81.61 |
Enterprise Value | $66.95M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.71, down 4.18% over 24 hours, reflecting bearish technical signals and recent earnings misses. The stock shows attractive valuation multiples with a P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results missed expectations, with revenue declining 10% year-over-year due to AI disruption pressures, as reported by MarketBeat on July 29, 2026.
The outlook remains cautious with significant AI-related headwinds compressing demand for freelance services. Near-term risks include execution challenges in a shifting competitive landscape, but the current low valuation may offer contrarian appeal if the company successfully adapts its strategy.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
